Latest Regulatory Approvals News

Eclipse Metals announces plans for a NASDAQ dual listing to boost its rare earth elements strategy and tap into North American capital markets, while maintaining its ASX presence.

Compumedics has secured a $2.15 million placement to fast-track commercialisation of its Somfit D device following early FDA approval, positioning the company for significant growth in the US home sleep testing market.

Emyria has secured a multi-year funding extension with Medibank to launch its Empax mental health programs in Brisbane, marking a key step in its national expansion. This insurer-backed initiative aims to improve access to treatment for complex conditions like treatment-resistant depression and PTSD.

Resolute Mining has agreed to support the sale of its 31.45 million shares in Loncor Gold to Chengtun Mining Group for C$1.38 per share, a move that will strengthen its balance sheet and accelerate key African projects.

Ainsworth Game Technology has lodged a supplementary statement supporting Novomatic’s unconditional takeover bid, even as its CEO resigns amid regulatory hurdles. The board unanimously recommends acceptance, with the offer deemed fair by an independent expert.

29Metals maintains steady copper output at Golden Grove despite seismic disruptions to zinc production, while progressing key growth projects and regulatory steps toward Capricorn Copper’s restart.

29Metals reports a steady copper output but significant zinc production decline due to seismic disruptions at Golden Grove, alongside rising operational costs and ongoing progress at Capricorn Copper.

Johns Lyng Group shares will halt trading following Supreme Court approval of its acquisition by Sherwood BidCo, controlled by Pacific Equity Partners.

Highfield Resources has locked in A$10 million through convertible notes from existing investors to tackle a key permit issue and push forward its flagship Muga Potash Project in Spain.

Smartpay Holdings Limited shareholders have overwhelmingly approved the proposed scheme of arrangement with Shift4 Holdings Limited, clearing a crucial hurdle towards finalising the acquisition.

Clarity Pharmaceuticals’ Co-PSMA Phase II trial shows its Cu-SAR-bisPSMA diagnostic agent detects more prostate cancer lesions than current standard imaging, promising earlier and more accurate recurrence detection.

Resouro Strategic Metals is on track to close its non-brokered private placement within the week, aiming to fund critical engineering work for its Tiros Titanium-Rare Earths Project in Brazil.